OM:ONCO

Stock Analysis Report

Executive Summary

Oncopeptides AB (publ), a pharmaceutical company, develops drugs for the treatment of cancer.


Snowflake Analysis

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Oncopeptides's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ONCO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-7.1%

ONCO

-1.9%

SE Biotechs

0.09%

SE Market


1 Year Return

9.8%

ONCO

-7.3%

SE Biotechs

22.0%

SE Market

Return vs Industry: ONCO exceeded the Swedish Biotechs industry which returned -7.3% over the past year.

Return vs Market: ONCO underperformed the Swedish Market which returned 22% over the past year.


Shareholder returns

ONCOIndustryMarket
7 Day-7.1%-1.9%0.09%
30 Day-2.4%2.3%4.7%
90 Day6.7%11.4%11.1%
1 Year9.8%9.8%-6.3%-7.3%26.9%22.0%
3 Year197.3%197.3%35.4%27.9%40.1%18.9%
5 Yearn/a36.8%59.3%46.5%15.4%

Price Volatility Vs. Market

How volatile is Oncopeptides's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oncopeptides undervalued compared to its fair value and its price relative to the market?

9.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ONCO (SEK131.7) is trading above our estimate of fair value (SEK3.66)

Significantly Below Fair Value: ONCO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ONCO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ONCO is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ONCO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ONCO is overvalued based on its PB Ratio (9.2x) compared to the SE Biotechs industry average (4.7x).


Next Steps

Future Growth

How is Oncopeptides forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

58.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ONCO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: ONCO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ONCO's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if ONCO's revenue is forecast to grow faster than the Swedish market.

High Growth Revenue: Insufficient data to determine if ONCO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ONCO is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Oncopeptides performed over the past 5 years?

-42.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ONCO is currently unprofitable.

Growing Profit Margin: ONCO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ONCO is unprofitable, and losses have increased over the past 5 years at a rate of -42.1% per year.

Accelerating Growth: Unable to compare ONCO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.6%).


Return on Equity

High ROE: ONCO has a negative Return on Equity (-92.94%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Oncopeptides's financial position?


Financial Position Analysis

Short Term Liabilities: ONCO's short term assets (SEK970.9M) exceed its short term liabilities (SEK165.2M).

Long Term Liabilities: ONCO's short term assets (SEK970.9M) exceed its long term liabilities (SEK31.3M).


Debt to Equity History and Analysis

Debt Level: ONCO is debt free.

Reducing Debt: ONCO has not had any debt for past 5 years.


Balance Sheet

Inventory Level: ONCO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ONCO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ONCO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ONCO has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -41.5% each year.


Next Steps

Dividend

What is Oncopeptides's current dividend yield, its reliability and sustainability?

0.19%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ONCO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ONCO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ONCO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONCO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ONCO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Jakob Lindberg (47yo)

8.3yrs

Tenure

kr4,998,000

Compensation

Dr. Jakob Lindberg, Med. Lic has been the Chief Executive officer of Oncopeptides AB since October 2011. Dr. Lindberg is a Venture Partner at Investor Growth Capital Europe. He is the Owner of Cellectricon ...


CEO Compensation Analysis

Compensation vs Market: Jakob's total compensation ($USD514.02K) is about average for companies of similar size in the Swedish market ($USD613.57K).

Compensation vs Earnings: Jakob's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jakob Lindberg
Chief Executive Officer8.3yrskr5.00m0.98% SEK71.8m
Rolf Larsson
0yrsno datano data
Rolf Lewensohn
0yrsno datano data
Joachim Gullbo
0yrsno datano data
Kristina Luthman
0yrsno datano data
Hans Ehrsson
0yrsno datano data
Peter Nygren
0yrsno datano data
Anders Martin-Löf
Chief Financial Officer1.5yrsno data0.0090% SEK658.3k
Christian Jacques
Executive VP0yrsno datano data
Rein Piir
Head of Investor Relations4.1yrsno data0.0045% SEK329.1k

3.0yrs

Average Tenure

60yo

Average Age

Experienced Management: ONCO's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christian Jacques
Executive VP0yrsno datano data
Jonas Brambeck
Independent Director12.1yrskr300.00kno data
Per Anders Samuelsson
Independent Director8.1yrskr300.00kno data
Cecilia Wennborg
Independent Director3yrskr452.00k0.011% SEK790.4k
Lori Kunkel
Member of Clinical Advisory Board0yrsno datano data
Jarl Jungnelius
Independent Director8.8yrskr419.00k0.014% SEK1.0m
Brian Stuglik
Independent Director1.8yrskr379.00kno data
Per Wold-Olsen
Chairman1.8yrskr853.00k0.12% SEK8.9m
Jennifer Jackson
Independent Director1.2yrskr168.00kno data
Paul Richardson
Member of Clinical Advisory Board0yrsno datano data

3.0yrs

Average Tenure

61yo

Average Age

Experienced Board: ONCO's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.4%.


Top Shareholders

Company Information

Oncopeptides AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncopeptides AB (publ)
  • Ticker: ONCO
  • Exchange: OM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr7.298b
  • Shares outstanding: 55.41m
  • Website: https://www.oncopeptides.se

Number of Employees


Location

  • Oncopeptides AB (publ)
  • Vastra Tradgardsgatan 15
  • Stockholm
  • Stockholm County
  • 111 53
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
0RN4LSE (London Stock Exchange)YesOrdinary SharesGBSEKFeb 2017
ONCOOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKFeb 2017
ONDDB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 2017
ONCOSBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBSEKFeb 2017

Biography

Oncopeptides AB (publ), a pharmaceutical company, develops drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/22 23:36
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.